Artelo Biosciences, Inc.
ARTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,993 | $5,696 | $4,324 | $2,839 |
| G&A Expenses | $4,115 | $4,234 | $5,963 | $4,602 |
| SG&A Expenses | $4,115 | $4,234 | $5,963 | $4,602 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,108 | $9,930 | $10,287 | $7,441 |
| Operating Income | -$10,108 | -$9,930 | -$10,287 | -$7,441 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $282 | $641 | $204 | $4 |
| Pre-Tax Income | -$9,826 | -$9,289 | -$10,083 | -$7,437 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,826 | -$9,289 | -$10,083 | -$7,437 |
| % Margin | – | – | – | – |
| EPS | -3.05 | -3.14 | -3.49 | -5.97 |
| % Growth | 2.9% | 10% | 41.5% | – |
| EPS Diluted | -3.05 | -3.14 | -3.49 | -5.97 |
| Weighted Avg Shares Out | 3,223 | 2,960 | 472 | 207 |
| Weighted Avg Shares Out Dil | 3,223 | 2,960 | 472 | 207 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $2 |
| Interest Expense | $0 | $0 | $5 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10,108 | -$9,930 | -$10,078 | -$7,437 |
| % Margin | – | – | – | – |